NCT01221935 - Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder | Biotech Hunter

Enrollment

2,701

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Major Depressive Disorder

Interventions

OTHER

Pristiq first-line treatment charts

300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment

OTHER

Pristiq second-line treatment charts

800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)).

OTHER

SNRI or SSRI first-line treatment charts

800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs) (excluding Pristiq) within the past 6 months as a first-line treatment.

OTHER

SNRI or SSRI second-line treatment charts

800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)(excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).